Hong Kong's FastMed Launches Doctor-Led GLP-1 Weight Loss Programme Amid Surge in Demand

FastMed, a Hong Kong-based telemedicine and dispensing service, has launched a medically supervised weight management programme. The initiative comes as demand for GLP-1 medications surges globally, while local markets face risks from unregulated sales. The company aims to provide a safe, doctor-led alternative to informal channels selling these prescription drugs without oversight.

The World Health Organization classifies obesity as a chronic disease. GLP-1-based treatments, such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), have seen explosive demand since 2023. Global sales jumped from around $17 billion in 2023 to over $40 billion by 2025, driven by official obesity treatment approvals and off-label use. The US leads with over 80% yearly growth, while Europe and emerging markets like China and Brazil follow closely.

In Hong Kong, many consumers turn to unregulated online sellers for weight-loss injections. These informal channels often bypass medical checks, raising concerns about ineffective or unsafe products. FastMed's programme counters this by requiring a full clinical assessment before any treatment begins.

The process starts with an online medical evaluation by a registered doctor. If suitable, patients receive a personalised treatment plan, followed by verification and delivery of the medication. FastMed ensures the same standards as in-clinic care, but without the need for in-person visits. This approach maintains privacy while meeting legal and safety requirements.

FastMed's programme offers a compliant route for accessing GLP-1 medications in Hong Kong. By enforcing doctor-led assessments, it reduces the risks linked to unregulated sales. The service aligns with global trends in obesity treatment while prioritising patient safety and convenience.